狂犬病毒中和抗体检测试验中病毒回归试验的重要性

狂犬病毒中和试验的病毒回归试验表明,病毒攻毒液的实际剂量与理论剂量不完全一致.建议在新版<中华人民共和国兽用生物制品质量标准>中增加对病毒攻毒实际剂量范围的规定,以使结果的判定更为合理.     

狂犬病病毒HEP-Flury M基因重排后在小鼠神经母细胞瘤细胞中的表型分析

【目的】探究狂犬病病毒HEP-Flury M基因重排对基因转录和蛋白表达的影响,揭示病毒在小鼠神经母细胞瘤(NA)细胞中的表型变化与M基因重排的相关性。【方法】通过荧光定量PCR、Western blot以及病毒在NA细胞中的生长和扩散试验,对亲本毒株rHEP-Flury和M基因重排毒株M2、M4在NA细胞中的基因转录、表达、生长和扩散进行比较。【结果】狂犬病病毒结构基因的转录和表达主要受病毒基因组RNA合成的影响,但是在一个完整转录过程中单个结构基因的转录比例与其所在位置相关,M基因重排病毒的Leader RNA (LeRNA)和L mRNA的转录比例显著高于亲本毒株rHEP-Flury。M基因重排病毒在NA细胞中的生长和扩散都劣于亲本毒株rHEPFlury。【结论】狂犬病病毒亲本毒株rHEP-Flury具有狂犬病病毒原始的基因组顺序,在NA细胞中的生长和扩散都明显优于M基因重排病毒。结构基因在基因组中的位置主要决定其在一次转录过程中的转录比例,进而影响病毒在NA细胞中的生长和扩散。     

上海市犬只狂犬病认定免疫点主要管理做法分析

强化犬只狂犬病免疫工作是从源头控制狂犬病的最有效措施。近年来,上海市按照《上海市养犬管理条例》的要求,通过严把免疫资质准入、规范内部管理、落实疫情报告责任、推进免疫质量考核等举措,使犬只狂犬病认定免疫点的布局日趋合理,文明服务更加规范,这已成为上海市民犬只狂犬病免疫的主渠道,免疫数量和质量逐年提升,构筑了良好的免疫屏障。今后在犬只狂犬病认定免疫点管理方面,上海市应强化疫苗源头管理,加大非法免疫惩处力度,合理认定免疫点整体布局,规范引导免疫行为和内部运行。     

狂犬病病毒糖蛋白膜外区基因在大肠埃希氏菌中的高效表达

为获得狂犬病病毒（RV）糖蛋白抗原，采用RT-PCR方法从狂犬病病毒ERA株中扩增了编码RV糖蛋白的全长基因，将其克隆于pMD18-T载体，再经PCR扩增出糖蛋白全长基因和膜外区基因，将其分别亚克隆至原核表达载体pET-28a（＋）、pET-32a（＋）和pGEX-4T-1中，经PCR和双酶切鉴定以及序列分析，表明已成功构建了重组质粒。将重组质粒转化到大肠埃希氏菌BL21（DE3）中进行表达，结果显示，克隆到pET-32a（＋）的糖蛋白膜外区基因表达量最高，目的蛋白表达量占菌体总蛋白的45．4％。经Western-blotting检测，不同载体表达的糖蛋白膜外区产物均可与兔抗RV多抗发生特异性反应，表明，重组蛋白具有良好的反应原性。     

Construction of Full-length cDNA of Recombinant Rabies Virus SRV9 Strain Expressing EgM123 Gene of Echinococcus granulosus

The aim of the experiment was to construct the recombinant rabies virus SRV₉ vaccine strain with EgM123 gene by reverse genetics technology and provide the technical means for effective prevention and control of rabies and hydatidosis in China's agricultural and pastoral areas.In this study,the structural protein N,P and L genes of rabies virus SRV₉ were synthesized using gene synthesis technology,which was based on the complete genome sequence of rabies virus SRV₉ and the fusion fragment of the N-P-M fusion fragment and the rabies G gene,through the carrier of enzyme insertion connection methods,the recombinant rabies virus L gene,N-P-M gene fusion fragment and G+EgM123+eGFP gene fusion fragment were successively recombined on the expression vector pcDNA3.1(-) to construct the full-length cDNA of recombinant rabies virus SRV₉ with EgM123 gene.The synthesized genes were constructed on pcDNA3.1(-) expression vector,and the results of transformation,plasmid digestion and gene sequencing showed that the length of N,P,L,N+P+M and G+EgM123+eGFP gene fragments were 1 365,1 107,6 471,3 160 and 3 256 bp,respectively.The full-length cDNA fragment of EgM123 gene recombinant rabies virus full-length cDNA was 12 465 bp,and the sequencing results of each gene fragment were 100%.In this experiment,the full-length cDNA fragment of recombinant EgM123 rabies and eukaryotic expression vectors of the N,P and L genes of rabies virus were successfully constructed,which could save EgM123 gene recombinant rabies by reverse genetics,it also provided the reference for the development of rabies and hydatid disease combined gene recombinant oral live vaccine.     

狂犬病灭活疫苗CVS-11株对牛的免疫效果

野生狐和貉狂犬病流行于新疆、内蒙古和黑龙江地区,是当地牛、羊和骆驼等家畜狂犬病的主要传染源。在国内尚无野生动物口服疫苗的前提下,对家畜进行狂犬病灭活疫苗接种,具有重要的公共卫生学意义。本研究利用国产犬用狂犬病灭活疫苗(CVS-11株)对牛进行了免疫效果和安全性评价。以不同剂量疫苗肌内注射免疫成年牛350头,通过比较免疫后狂犬病病毒中和抗体水平和持续期,确定犬用狂犬病灭活疫苗(CVS-11株)在牛的最佳免疫剂量为1次性注射2剂量疫苗,免疫持续期为1年。结果表明,犬用狂犬病灭活疫苗(CVS-11株)免疫牛时,具有较高的免疫原性和安全性,适用于牛等大型动物的狂犬病注射免疫。     

Recurrent Temporary Paralysis Reported After Human Rabies Post‐Exposure Prophylaxis

Adverse events can occur after rabies post‐exposure prophylaxis (PEP), and linkage to causality is often difficult to determine. We report a case of recurrent temporary paralysis that began immediately after the initiation of rabies PEP in a man exposed to a bat. The recurrent temporary paralysis first occurred in the patient after his initial dose and then again after day 3 of his rabies PEP. The PEP was terminated prior to a serologic response. The patient continued to experience numerous discrete episodes of temporary paralysis for over two years.     

Surveillance of Human Rabies by National Authorities – A Global Survey

Effective prevention of deaths due to human rabies is currently hampered by a lack of understanding of the scale of the problem, and the distribution of both animal and human cases across countries, regions and continents. Unfortunately, despite the severity of the disease, accurate data on which to assess these questions and to prioritize and direct public health interventions are not available for many parts of the world. This survey sought to understand the current global situation regarding the surveillance of human rabies. Data were collected from 91 countries across all continents and all categories of human rabies risk, generating the most complete and representative global data set currently available. Respondents were asked key questions about whether human rabies was a notifiable disease, how the surveillance system for human rabies operated and whether the respondent considered that the surveillance system was working effectively. Across the 91 countries from which data were collated, human rabies was a notifiable disease in all but eight. Despite international guidance, surveillance systems were very varied. Even where rabies is a notifiable disease, many countries had surveillance system judged to be ineffective, almost all of these being high and moderate rabies risk countries in Africa and Asia. Overall, 41% of the population covered by this survey (around 2.5 billion people) live in countries where there is no or ineffective rabies surveillance. The lack of robust surveillance is hindering rabies control efforts. However, whilst worldwide rabies surveillance would be improved if rabies were notifiable in all countries, many other challenges to the implementation of effective global human rabies surveillance systems remain.     

Evaluation of 6 ONRAB Ultralite bait flavor matrices delivered to coyotes (Canis latrans): Implications for oral rabies vaccination

The spread of rabies in terrestrial wildlife throughout the United States is primarily controlled through oral rabies vaccination. Relatively low bait acceptance and seroconversion rates by some target species have prompted investigation into an alternative to the RABORAL V-RG bait currently used. In Canada, ONRAB Ultralite baits are used to vaccinate raccoons (Procyon lotor) and striped skunks (Mephitis mephitis). Comparative studies between RABORAL V-RG and ONRAB found higher seroconversion rates among raccoons that ingested ONRAB, suggesting that it may be a suitable alternative. However, ONRAB has not been evaluated in many rabies reservoir species, including coyotes (Canis latrans). Vaccination of coyotes is a critical element in preventing reemergence of canine strain of rabies in the United States. We evaluated flavor preference of ONRAB Ultralite oral rabies vaccine baits by coyotes. Preferences among bait types differed (Friedman χ² = 13.28; df = 5; P = 0.02). Of the 6 bait flavors evaluated, cheese ranked the highest, followed by fish, chicken, sugar-vanilla, egg, and bacon flavors. Pairwise trials among the top 3 flavors (cheese, fish, and chicken) showed no difference (Friedman χ² = 3.00; df = 2; P = 0.22). Our research suggests that among the bait flavors we evaluated, cheese, fish, or chicken-flavored baits may be an appropriate flavor for delivery of ONRAB Ultralite baits to coyotes.